Drug Target Review2025-11-20T13:30:37
A new CAR-T treatment developed in Switzerland has shown striking early success against glioblastoma, one of the deadliest brain cancers, and is now moving towards human trials.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-11T14:00:00
Sponsored by Cell Signaling Technology
2025-05-14T14:30:00
Sponsored by Abzena
2023-07-04T10:05:58
Sponsored by Revvity
2023-02-23T14:02:18
Sponsored by bit.bio
2023-01-06T16:37:30
Sponsored by Catalent
2025-04-22T14:58:00
Sponsored by Takara Bio USA
Site powered by Webvision Cloud